Standard BioTools Inc. (NASDAQ:LAB) Director Purchases $98,250.00 in Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 75,000 shares at $1.31 each, totaling $98,250 on August 13. This acquisition increased their ownership by 0.13%, bringing their total shares to 59,466,780, valued at approximately $77.9 million. The director also made additional purchases of 150,000 shares at $1.22 and 133,220 shares at $1.21 shortly after. Analysts have recently adjusted ratings on Standard BioTools, with some downgrading from 'buy' to 'hold'.

Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L acquired 75,000 shares of the business's stock in a transaction on Wednesday, August 13th. The stock was acquired at an average cost of $1.31 per share, for a total transaction of $98,250.00. Following the transaction, the director directly owned 59,466,780 shares in the company, valued at $77,901,481.80. The trade was a 0.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Casdin Partners Master Fund, L also recently made the following trade(s):

On Friday, August 15th, Casdin Partners Master Fund, L purchased 150,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.22 per share, for a total transaction of $183,000.00.
On Thursday, August 14th, Casdin Partners Master Fund, L purchased 133,220 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.21 per share, for a total transaction of $161,196.20.

Standard BioTools Stock Performance

Standard BioTools stock opened at $1.23 on Friday. The stock has a 50-day moving average of $1.26 and a two-hundred day moving average of $1.20. Standard BioTools Inc. has a one year low of $0.92 and a one year high of $2.32. The stock has a market cap of $467.18 million, a PE ratio of -3.84 and a beta of 1.32.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LAB. Wall Street Zen raised Standard BioTools from a "sell" rating to a "hold" rating in a research report on Saturday. Cowen cut Standard BioTools from a "buy" rating to a "hold" rating in a research note on Wednesday. Finally, TD Cowen cut Standard BioTools from a "buy" rating to a "hold" rating and set a $1.55 price objective for the company. in a research note on Wednesday.

View Our Latest Research Report on Standard BioTools

Institutional Investors Weigh In On Standard BioTools

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LAB. Two Sigma Securities LLC purchased a new position in shares of Standard BioTools in the fourth quarter worth about $30,000. Jump Financial LLC acquired a new position in Standard BioTools in the 1st quarter worth approximately $26,000. Aquatic Capital Management LLC acquired a new position in Standard BioTools in the 4th quarter worth approximately $45,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in Standard BioTools by 115.6% in the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock worth $29,000 after purchasing an additional 14,541 shares in the last quarter. Finally, CWM LLC grew its stake in shares of Standard BioTools by 101.8% during the 1st quarter. CWM LLC now owns 29,705 shares of the company's stock worth $32,000 after purchasing an additional 14,984 shares during the period. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Standard BioTools Company Profile

(Get Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.